The overarching goal of the Tissue and Pathology Core (TPC) is to facilitate translational research involving the acquisition or use of biological samples within the SPORE. To accomplish this goal, the Core will offer a range of services for SPORE investigators. These include: 1) Providing a tissue and blood repository;2) Collecting, storing, processing, and analyzing tissue and blood from participants on SPORE clinical trials;and 3) Providing a variety of readily accessible pathology and technical services, integrated with clinical information. In addition to standard pathology techniques, the TPC will offer several state-of-the- art technologies including circulating tumor cell capture and analysis. Lastly, the TPC will centralize and prioritize access of biological samples to investigators collected in the SPORE. A key strength of the TPC is the ability to bank frozen tumor tissue. The Core has a pre-existing collection of over 2,600 frozen breast cancer specimens acquired during the previous SPORE and this resource will continue to be expanded. The Core also will maintain a blood sample repository that will build upon the current collection of samples from 10,000 patients with breast cancer and from 2,400 individuals at high risk of developing breast cancer. In order to optimize the utility of the specimen collections for translational research, the samples in the repository are linked to clinical data through caTissue. The TPC will work closely with the Clinical Trials Core to procure research biopsies and other tissues from participants on SPORE clinical trials. The TPC will use caTissue to catalogue these specimens as well. Importantly, the Core will be directly involved in the analysis of these specimens, and will interact extensively with the four projects. To ensure that project-related tissue based research is seamless;a specific team pathologist from the TPC has been identified as a collaborator for each project. In addition to working with SPORE investigators, the Core will work with investigators throughout the DF/HCC, with other Breast Cancer SPORE programs, and with researchers at centers around the world. The TPC facilitates clinical research involving the acquisition or use of biological samples within the SPORE. Three of the four projects have proposed clinical trials that include research biopsies (Projects 2, 3, 4). The TPC will oversee the collection, storage, quality assessment, and processing of these biopsies. During the course of the SPORE, we anticipate supporting other investigators who will conduct tissue-intensive trials either as part of the projects or through a career development program award or developmental project.

Public Health Relevance

The Tissue and Pathology Core facilitates translational research involving the acquisition or use of biological samples. The collection of tissue and blood from healthy and diseased women is vital to translational research. Having the TPC resource will advance our ability to prevent, diagnose and treat breast cancer. The Core will enable the SPORE toward translational discoveries in the near-term, and a new wave of scientific challenges.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA168504-01A1
Application #
8607760
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (O1))
Project Start
2013-09-17
Project End
2018-07-31
Budget Start
2013-09-17
Budget End
2014-07-31
Support Year
1
Fiscal Year
2013
Total Cost
$184,409
Indirect Cost
$26,276
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Zhang, Jing; Gao, Xueliang; Schmit, Fabienne et al. (2017) CRKL Mediates p110?-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells. Cell Rep 20:549-557
Heng, Yujing J; Lester, Susan C; Tse, Gary Mk et al. (2017) The molecular basis of breast cancer pathological phenotypes. J Pathol 241:375-391
Rondinelli, Beatrice; Gogola, Ewa; YĆ¼cel, Hatice et al. (2017) EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol 19:1371-1378
Breitkopf, Susanne B; Taveira, Mateus De Oliveira; Yuan, Min et al. (2017) Serial-omics of P53-/-, Brca1-/- Mouse Breast Tumor and Normal Mammary Gland. Sci Rep 7:14503
Thorpe, Lauren M; Spangle, Jennifer M; Ohlson, Carolynn E et al. (2017) PI3K-p110? mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85?. Proc Natl Acad Sci U S A 114:7095-7100
Goel, Shom; DeCristo, Molly J; Watt, April C et al. (2017) CDK4/6 inhibition triggers anti-tumour immunity. Nature 548:471-475
Simond, A M; Rao, T; Zuo, D et al. (2017) ErbB2-positive mammary tumors can escape PI3K-p110? loss through downregulation of the Pten tumor suppressor. Oncogene 36:6059-6066
Spangle, Jennifer M; Roberts, Thomas M; Zhao, Jean J (2017) The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. Biochim Biophys Acta 1868:123-131
Liu, Hui; Murphy, Charles J; Karreth, Florian A et al. (2017) Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov :
Willis, Nicholas A; Frock, Richard L; Menghi, Francesca et al. (2017) Mechanism of tandem duplication formation in BRCA1-mutant cells. Nature 551:590-595

Showing the most recent 10 out of 54 publications